0 129

Cited 9 times in

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients

 Kihyun Kim  ;  Seok Jin Kim  ;  Verena Voelter  ;  Cheolwon Suh  ;  Sung-Soo Yoon  ;  Je-Jung Lee  ;  Jae-Yong Kwak  ;  Hun-Mo Ryoo  ;  Yang Soo Kim  ;  Joon Ho Moon  ;  Seong Kyu Park  ;  Sung-Hyun Kim  ;  Yeung-Chul Mun  ;  Jin Seok Kim  ;  Hyeon-Seok Eom  ;  Deog-Yeon Jo  ;  Hyun Jung Jun  ;  Ki-Hwan Kim  ;  Jeong-Ok Lee  ;  Jae Hoon Lee  ;  Chang-Ki Min 
 ANNALS OF HEMATOLOGY, Vol.93(1) : 113-121, 2014 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Boronic Acids/pharmacology ; Bortezomib ; Chromosome Aberrations ; Combined Modality Therapy ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Drug Evaluation ; Drug Resistance, Neoplasm ; Fatigue/chemically induced ; Female ; Follow-Up Studies ; Gastrointestinal Diseases/chemically induced ; Hematologic Diseases/chemically induced ; Hematopoietic Stem Cell Transplantation ; Humans ; Kaplan-Meier Estimate ; Korea ; Male ; Middle Aged ; Multiple Myeloma/drug therapy* ; Multiple Myeloma/genetics ; Multiple Myeloma/surgery ; Pyrazines/pharmacology ; Retrospective Studies ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Thalidomide/pharmacology ; Treatment Outcome
Lenalidomide ; Relapsed myeloma ; Korean
We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.